Ella Fitszimmons
Sep 10, 2008

Xian Janssen shifts two brands to Bates141

BEIJING - Bates141 has secured the creative duties for two of Johnson & Johnson subsidiary Xian Janssen Pharmaceutical's over-the-counter products, following a pitch contested by two other agencies.

Xian Janssen shifts two brands to Bates141
DMG was the incumbent for Motilium, which has a reported media spend of US$30 million, though it could not be confirmed whether it attempted to defend the account.

Motilium (a stomach motility drug) is currently the most successful OTC medication across categories in China. The second brand, Mylanta, is a new antacid.

Source:
Campaign China

Follow us

Top news, insights and analysis every weekday

Sign up for Campaign Bulletins

Related Articles

Just Published

Jan 29, 2026

Gemini 3 becomes the default model for AI Overviews

A pair of updates from Google see the tech giant attempt to gain a further foothold in the battle for AI-powered search supremacy.

Jan 29, 2026

Google criticised after blocking measurement ...

YouTube owner sent a 'cease and desist' letter to Barb and Kantar Media.

Jan 29, 2026

Inside Campaign Connect Indonesia: what matters to ...

Candid conversations on growth, AI and the cultural trade-offs of scaling brands, with more than 100 marketers in the room.

Jan 29, 2026

Meta hits $200 billion revenue milestone on ...

Meta reports double‑digit year-on-year revenue growth, with advertising once again accounting for almost all of the top line.